Phase II trial of gemcitabine/doxorubicin/paclitaxel administered every other week in patients with metastatic breast cancer.

Clinical breast cancer

Volumn 1, Issue 3, 2000, Pages 226-232

  Sanchez Rovira P ^a   Jaen A ^a   Gonzalez E ^a   Porras, I ^a   Duenas M R ^a   Medina, B ^a   Mohedano, N ^a   Fernandez M ^a   Martos, M ^a   Lozano, A ^a  

^a Hosp Univ Ciudad de Jaén   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DOXORUBICIN; DRUG DERIVATIVE; GEMCITABINE; PACLITAXEL;

ADULT; AGED; ARTICLE; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DISEASE COURSE; DRUG ADMINISTRATION; DRUG EFFECT; DRUG MONITORING; FEMALE; FOLLOW UP; HEART; HUMAN; METASTASIS; MIDDLE AGED; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; DISEASE PROGRESSION; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; FOLLOW-UP STUDIES; HEART; HUMANS; MIDDLE AGED; NEUTROPENIA; PACLITAXEL; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0034309157     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2000.n.019     Document Type: Article

References (0)